Interview with Patrik De Haes, Chief Executive Officer, ThromboGenics
Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud…
Address: Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Tel: +32 (0) 16 75 13 10
Web: http://thrombogenics.com/
Thrombogenics NV is a Belgium-based biopharmaceutical company focused on the discovery and development of medicines for the treatment of eye disease, vascular disease and cancer. The Company’s lead drug candidateocriplasmin (microplasmin), completed two phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). The TN-402 (Anti-factor VIII) drug candidate against deep vein thrombosis and atrial fibrillation is in phase I of the clinical trials. The TB-403 anticancer agent was licensed to F. Hoffmann La Roche AG which will subject it to phase II clinical trials. The Staphylokinase candidate against Acute myocardial infarction (AMI) successfully completed phase II clinical trials. The Company has its Branch in Ireland and also subsidiary in the United States.
The Company’s lead drug candidateocriplasmin (microplasmin), completed two phase III clinical trials for the pharmacological treatment of symptomatic vitreomacular adhesion (sVMA). The TN-402 (Anti-factor VIII) drug candidate against deep vein thrombosis and atrial fibrillation is in phase I of the clinical trials. The TB-403 anticancer agent was licensed to F. Hoffmann La Roche AG which will subject it to phase II clinical trials. The Staphylokinase candidate against Acute myocardial infarction (AMI) successfully completed phase II clinical trials. The Company has its Branch in Ireland and also subsidiary in the United States.
Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud…
Today, B&M differentiates itself by what it calls its ‘fluency’ in the way you think, work and behave which enables you to navigate the legal complexities across practices and boarders…
Mr Baudier, what inspired you when you joined the company back in 1978 and what are your main goals today? Prior to joining SMB Laboratories, I worked in a publishing…
Today, B&M differentiates itself by what it calls its ‘fluency’ in the way you think, work and behave which enables you to navigate the legal complexities across practices and boarders…
Dr De Backer looking into your background, we see that you have a background in aerospace engineering and applied biomedical computational fluid dynamics that is riddled with awards for your…
Dr De Haes, as the CEO of ThromboGenics for the last five years, can you provide us with an overview of the company’s main achievements that you are most proud…
October marks the completion of your first full year as general manager of Cegedim’s Belgian affiliate. To what extent do you feel that the skills you’ve acquired in your career…
October marks the completion of your first full year as general manager of Cegedim’s Belgian affiliate. To what extent do you feel that the skills you’ve acquired in your career…
World Courier’s General Manager, Belgium After accumulationg an almost combined five decades of experience at World Courier, can you please tell our readers what it is that attracted the both…
Mr Noel Foucart, looking into your background, we see that you have accumulated almost 3 decades of experience at World Courier. Can you tell our readers what it is that…
What was the motivation behind the establishment of BeCRO and why was it only established in 2010 given the strength of Belgium’s clinical trials industry? Philippe van der Hofstadt: Prior…
Having worked in internal clinical research for Eli Lilly for 14 years, from 1993 – 2007, what has this experience taught you about what pharmaceutical companies need in an outsourcing…
Deloitte is certainly renowned for its strong network of international expertise in the field of life sciences having teams in all of the crucial markets able to cater to their…
See our Cookie Privacy Policy Here
